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Abstract
The renin–angiotensin system modulates insulin action. Angiotensin type 1
receptor exerts a deleterious effect, whereas the angiotensin type 2 receptor
(AT2R) appears to have beneficial effects providing protection against insulin
resistance and type 2 diabetes. To further explore the role of the AT2R on
insulin action and glucose homeostasis, in this study we administered C57Bl/6
mice with the synthetic agonist of the AT2R C21 for 12 weeks (1 mg/kg per
day; ip). Vehicle-treated animals were used as control. Metabolic parameters,
glucose, and insulin tolerance, in vivo insulin signaling in main insulin-target
tissues as well as adipose tissue levels of adiponectin, and TNF-a were
assessed. C21-treated animals displayed decreased glycemia together with unal-
tered insulinemia, increased insulin sensitivity, and increased glucose tolerance
compared to nontreated controls. This was accompanied by a significant
decrease in adipocytes size in epididymal adipose tissue and significant
increases in both adiponectin and UCP-1 expression in this tissue. C21-treated
mice showed an increase in both basal Akt and ERK1/2 phosphorylation levels
in the liver, and increased insulin-stimulated Akt activation in adipose tissue.
This positive modulation of insulin action induced by C21 appeared not to
involve the insulin receptor. In C21-treated mice, adipose tissue and skeletal
muscle became unresponsive to insulin in terms of ERK1/2 phosphorylation
levels. Present data show that chronic pharmacological activation of AT2R
with C21 increases insulin sensitivity in mice and indicate that the AT2R has
a physiological role in the conservation of insulin action.
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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Introduction
The renin–angiotensin system (RAS) is an important
endocrine system that regulates renal, cardiac, and vas-
cular physiology, either by system effects via the circu-
lation, or via local effects within tissues (Ferrario et al.
2014; Karnik et al. 2015; Carey 2017). Angiotensin
(Ang) II is a key hormone in this system. It binds with
high affinity to two receptors, the angiotensin type-1
receptor (AT1R) and the angiotensin type-2 receptor
(AT2R) (Ferrario et al. 2014; Karnik et al. 2015; Carey
2017). Most of the actions of Ang II are mediated by
the AT1R (Booz and Baker 1996; Jones et al. 2008;
Karnik et al. 2015; Carey 2017; Padia and Carey 2013).
The in vivo physiological functions of the AT2R are
still not clearly defined, but, in general, it opposes the
actions of the AT1R (Padia and Carey 2013; Paulis
et al. 2016; Carey 2017). The AT2R is abundantly and
ubiquitously expressed in the developing rat fetus and
neonatal tissues, where it supports organ development
and differentiation. However, its expression declines
quickly during the neonatal period showing a relatively
low expression compared to AT1Rs in most adult tis-
sues (Ferrario et al. 2014; Karnik et al. 2015; Carey
2017). In fact, the AT2R is expressed at low levels in
the normal adult cardiovascular system, adrenal gland,
kidney, brain, uterine myometrium, and skin. There are
also some examples of tissues that contain more AT2R
than AT1R, such as the adrenal medulla, pancreas, and
discrete areas of the brain (Ozono et al. 1997; Wang
et al. 1998; Allen et al. 1999; Miyata et al. 1999; Padia
and Carey 2013; Shao et al. 2013; Karnik et al. 2015;
Carey 2017). The AT2 receptor density increases in tis-
sues under pathologic conditions in which inflammation
and tissue remodeling occur (Booz and Baker 1996;
Lemarie and Schiffrin 2010; Namsolleck et al. 2014;
Karnik et al. 2015; Carey 2017). Thus, the modulation
of the counterbalance between AT1Rs and AT2Rs has
an important therapeutic implication in pathological
conditions such as atherosclerosis, insulin resistance,
diabetes mellitus, nephropathy, and pulmonary fibrosis
(Padia and Carey 2013; Paulis et al. 2016).
Ang II plays a significant role in the development of
insulin resistance (Folli et al. 1997; Henriksen 2007; Favre
et al. 2015). Chronic Ang II elevation impairs insulin sen-
sitivity and leads to insulin resistance through an AT1R-
dependent mechanism (Folli et al. 1997; Henriksen 2007;
Favre et al. 2015). Indeed, AT1R antagonists improve
insulin resistance and reduce the incidence of new-onset
diabetes (Folli et al. 1997; Henriksen 2007; Lee et al.
2008b; Shiuchi et al. 2004). However, whether the AT2R
actively impacts on insulin sensitivity remains to be eluci-
dated. Pharmacological antagonism of the AT2R with the
nonpeptide antagonist PD123319 has indicated a partici-
pation of this receptor in insulin sensitivity and glucose
homeostasis. Acute infusion of PD123319 has been shown
to decrease skeletal muscle glucose uptake in rats (Chai
et al. 2010, 2011).
Systemic AT2 receptor blockade reduced the b-cell to
a-cell ratio of neonate islets and impaired their insulin
secretory function and glucose tolerance (Leung et al.
2014). Recently, we have demonstrated that chronic
AT2R blockade with PD123319 reduces the activity of
components of main insulin signaling pathways (e.g.,
insulin receptor and Akt) in mice (Mu~noz et al. 2017).
The discovery of the selective, nonpeptidic AT2R recep-
tor agonist, Compound 21 (C21), has significantly
advanced our current knowledge of AT2R function
(Wan et al. 2004). Administration of C21 improved
insulin sensitivity in both type 2 diabetic mice and
high-fructose/high-fat fed rats (Ohshima et al. 2012;
Shum et al. 2013). Stimulation of pancreatic AT2R with
C21 significantly enhanced insulin synthesis and secre-
tion in adult rats (Nag et al. 2015). Moreover, treatment
with C21 prevented streptozotocin induced apoptosis of
pancreatic ß-cells in type 1 diabetic rats (Shao et al.
2014). This beneficial effect on islet cell function and
regeneration appears to be via proliferative and antiox-
idative pathways (Wang et al. 2017). Administration of
C21 has recently been shown to enhance insulin delivery
and metabolic action in skeletal muscle (Yan et al.
2018). Remarkably, unlike results obtained from AT2R
stimulation or antagonism, information obtained from
AT2R-KO mice has not been consistent so far (Shiuchi
et al. 2004; Yvan-Charvet et al. 2005; Samuel et al. 2013;
Noll et al. 2015).
In view of available information suggesting a role for
the AT2R in metabolism, the aim of the current work
was to determine if the AT2R has a physiological role in
the modulation of insulin sensitivity and in the control of
glucose homeostasis in normal mice. For this, C57BL/6
male mice were treated with daily intraperitoneal injec-
tions of C21 for 12 weeks. Metabolic parameters, insulin,
and glucose tolerance tests, as well as the status of insulin
signaling in main insulin-target tissues were analyzed.
Specifically, we measured the abundance and phosphory-
lation status of essential insulin signaling components
(Boucher et al. 2014), such as the insulin receptor (IR),
Akt, and extracellular signal-regulated kinase (ERK)-1 and
-2, in the liver, adipose tissue, and skeletal muscle. We
found that C21-treated animals displayed increased insu-
lin sensitivity and glucose tolerance compared to non-
treated controls. This was accompanied by a significant
decrease in adipocytes size in epididymal adipose tissue
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and significant increases in both adiponectin and UCP-1
expression in this tissue. C21-treated mice also showed
increased insulin-mediated Akt activation in adipose tis-
sue. Collectively, we provide evidence for an improvement
of insulin sensitivity in vivo by chronic AT2R activation
through C21, which suggests AT2R stimulation as a possi-
ble new therapeutic approach to improve insulin action.
Materials and Methods
Study design
All experiments were approved by the Institutional Ani-
mal Care and Use Committee of the School of Pharmacy
and Biochemistry of the University of Buenos Aires.
Twenty-four male C57BL/6 mice (8 week old) were
obtained from School of Veterinary Sciences, National
University of La Plata (La Plata, Argentina). Animals were
maintained under controlled light and temperature condi-
tions and had free access to water and standard chow diet.
To evaluate the effects of chronic AT2R agonism, after
1 week of acclimation (9 weeks of age), animals were ran-
domly distributed into two groups: animals treated with
saline (control group) (n = 12), and animals treated with
C21 (C21 group); (n = 12). For 12 weeks, all animals
received a daily intraperitoneal (i.p.) injection of either
0.1 mL saline solution (control) or C21 (1 mg/kg; Vicore
Pharma AB, G€oteborg, Sweden). The dose of C21 was
selected based on previously published protocols (Samuel
et al. 2013; Nag et al. 2015; Chow et al. 2016) and it is
close to the upper limit of therapeutic application of C21.
The dose of C21 was adjusted weekly based on body
weight changes. On week 11, a glucose tolerance test
(GTT) was performed, and after a 2-day resting period,
mice were subjected to an insulin tolerance test (ITT). At
the end of the study in week 12, mice were injected with
either saline or insulin as described below, euthanized and
blood and tissues were collected as described below.
Glucose and insulin tolerance tests
Mice were fasted for 6 h (8:00 AM–14:00 PM) prior to com-
mencement of GTT. Briefly, baseline glucose levels were
sampled from tail blood using a commercial glucometer
(Accu-Check,Roche Diagnostics Corp., Indianapolis, IN).
Then, mice were injected I.P with 2 g of glucose per kilo-
gram of body weight (BW) using a 20% glucose solution
(w/v). and blood glucose was measured at 15, 30, 60, and
120 min postinjection. ITT: Mice were fasted for 6 h, and
then injected I.P. with 1 IU porcine insulin (Sigma-
Aldrich) per kilogram of body weight. Blood glucose was
measured at 0, 15, 30, 45, 60, and 120 min. The data for
both GTT and ITT are presented as absolute values.
Acute insulin stimulation and tissue
collection
After 12 weeks of C21 treatment, mice were fasted for 6 h
(8:00 AM-14:00 PM), anesthetized by the i.p. administra-
tion of a mixture of ketamine and xylazine (50 and 1 mg/
kg, respectively), and submitted to the surgical procedure
as soon as anesthesia was assured by the loss of pedal and
corneal reflexes. The abdominal cavity was opened, the
vena cava was exposed, and a dose of 10 IU porcine insu-
lin/kg body weight dissolved in 0.2 mL of normal saline
(0.9% NaCl) was injected via this vein. To obtain data
under basal conditions, mice received an injection of
vehicle. The liver, adipose tissue (epididymal), and skele-
tal muscle (hindlimb), were removed after 1, 3, and
6 min, respectively. Serum was obtained from blood of
saline-injected animals by centrifugation (3200g for
10 min at 4°C). Tissues and an aliquot of serum (for
insulin determination) were kept at 80°C until analysis.
Another aliquot of serum was used for determination of
circulating triglyceride (TG) and cholesterol concentra-
tions the same day of the sacrifice.
Tissue homogenization,
immunoprecipitation, and immunoblotting
Approximately 500 mg of tissue samples were homoge-
nized in 0.5 mL ice-cold homogenization buffer contain-
ing 1% Triton together with phosphatase and protease
inhibitors, as described previously (Mu~noz et al. 2017,
2009). Tissue extracts were centrifuged at 100,000g for
1 h at 4°C to eliminate insoluble material, and protein
concentration in the supernatants was measured using the
bicinchoninic acid assay (Pierce BCA Protein Assay
Reagent; Thermo Scientific, Waltham, MA). For immuno-
precipitation, equal amounts of tissue extracts (2 mg total
protein in a final volume of 0.2 mL) were incubated at
4°C overnight with an anti-IR antibody directed against
the IR b-subunit at a final concentration of 4 mg/mL.
After incubation, 15 lL protein A-Sepharose 50% v/v
were added to the mixture. Additional samples were incu-
bated in the absence of immunoprecipitating antibody to
corroborate that the precipitated proteins were specifically
recognized by the immunoprecipitating antibody and not
by protein A-Sepharose. The preparation was further
incubated with constant rocking for 2 h at 4°C and then
centrifuged at 1000g for 30 sec. The supernatant was dis-
carded and the precipitate was washed three times with
buffer containing 0.05 mol/L Tris, 0.01 mol/L sodium
vanadate, and 1% w/v Triton X-100 (pH 7.4). The final
pellet was resuspended in 50 lL Laemmli buffer, boiled
for 5 min, and stored at 20°C until electrophoresis.
Briefly, equal amounts of solubilized protein (40 lg) were
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separated by SDS-PAGE. Proteins were then transferred
to PVDF membranes and blotted with antiphospho-IR,
antiphospho-Akt, and antiphospho-Erk1/2 antibodies
(1:2000 dilution for all antibodies). The abundance of
adiponectin and TNF-a in adipose tissue was detected in
tissue lysates using specific antibodies at 1:2000 dilution;
GAPDH was used as a loading control at a 1:10,000 dilu-
tion. Immunoblotting was performed according to previ-
ously described protocols (Mu~noz et al. 2009).
Imunoprecipitated IR samples were subjected to
immunoblotting with either a specific antiphosphoty-
rosine or with the same antibody used for immunopre-
cipitation to determine protein abundance of the IR. The
abundance of Akt, and ERK1/2 was detected in tissue
lysates using the corresponding antiprotein antibodies at
1:2000 dilution. After extensive washing, membranes were
incubated with the appropriate secondary HRP-coupled
antibody at 1:20,000 dilution and processed for enhanced
chemiluminescence (ECL) using the Pierce ECL plus Wes-
tern blotting detection system (ThermoFisher Scientific,
Waltham, MA). Bands were quantified using Gel-Pro
Analyzer 4.0 (Media Cybernetics, Bethesda, MD). The
content of GADPDH in both immunoprecipitated and
solubilized protein extracts was used as a loading control
and was assessed in independent inmunoblottings using
the same volume of samples used for determination for
analysis of the phosphorylation and content of insulin
signaling molecules.
Assessment of blood chemistry
Plasma cholesterol and triglycerides were measured with
enzymatic colorimetric assay kits (Wiener Lab, Rosario,
Argentina). Serum insulin levels were assessed using a
mouse insulin ELISA kit (Crystal Chem, Downers Grove,
IL).
Immunohistochemistry
Portions of epididymal adipose tissue of each animal were
fixed in phosphate-buffered 10% formaldehyde (pH 7.2)
and embedded in paraffin. Three micrometer sections
were cut and processed for immunohistochemical study.
Immunolabeling of specimens was carried out with a
modified avidin–biotin–peroxidase complex technique
using a Vectastain ABC kit (Universal Elite; Vector Labo-
ratories, Burlingame, CA). Following deparaffinization
and rehydration, sections were washed in PBS for 5 min.
Quenching of endogenous peroxidase activity was
achieved by incubating the sections for 30 min in 1%
hydrogen peroxide in methanol. After being washed in
PBS (pH 7.2) for 20 min, they were incubated with
blocking serum for 20 min. The sections were then
incubated with the primary antibody, rinsed in PBS, and
incubated with biotinylated universal antibody for
30 min. After being washed in PBS, the specimens were
incubated for 40 min with Vectastain Elite ABC reagent
(Vector Laboratories, Burlingame, CA) and exposed for
5 min to 0.1% diaminobenzidine (Polysciences, Warring-
ton, PA) and 0.2% hydrogen peroxide in 50 mmol/L Tris
buffer, pH 8. Antibodies against adiponectin, TNF-a and
nitrotyrosine were used at a 1:200 dilution, the antibody
against UCP-1 was used at 1:500 dilution. All observa-
tions were performed using light microscopy (E400;
Nikon Instruments, Melville, NY) at a 910 magnification,
and histological images were captured with a digital cam-
era and processed by an image analyzer (Image-Pro Plus
4.5 for Windows; Media Cybernetics, Silver Spring, MD).
Immunolocalization was calculated by computer for adi-
pose tissue using the image analyzer and expressed as per-
centage of the area with positive staining for adiponectin,
nitrotyrosine-containing proteins, TNF-a, and UCP-1. In
all cases, two independent observers performed a blinded
evaluation, and the mean percentage value was then
calculated.
Morphological analysis of adipose tissue
Epididymal adipose tissue samples, preserved in buffered
formalin solution, were used to prepare 3-lm-thick paraf-
fin-embedded sections that were deparaffinized in xylene
and rehydrated to water through ethanol at 100°, 96°,
and 80°C (Mu~noz et al. 2009). For each individual sam-
ple, adipocyte size was measured in four microscopic
fields separated by at least 100 lmol/L (in single-blinded
condition). The size of 200 adipocytes was determined for
each mouse. Images were acquired using a Nikon E400
microscope at x10 magnification after hematoxylin-eosin
(H & E) staining. The adipocyte diameter was expressed
in lm.
Materials and reagents
The rabbit polyclonal antiinsulin receptor (IR) b-subunit
(C19; sc-711), the mouse monoclonal antiphosphoty-
rosine (PY99; sc-7020), the goat polyclonal anti-rabbit
IgG conjugated with HRP (sc-2004), the goat anti-mouse
IgG-HRP (sc-2005), and rabbit anti-goat IgG-HRP (sc-
2768) antibodies were purchased from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA). The rabbit poly-
clonal antibody antiphospho-Akt-S473 (4060), the rabbit
polyclonal antibody antiphospho-Akt-T308 (9275), the
anti-Akt (pan) rabbit monoclonal antibody (C67E7) that
detects endogenous levels of total AKT1, AKT2, and
AKT3 protein, the rabbit monoclonal, the rabbit mono-
clonal antibody antiphospho-ERK1/2, that detects ERK-1
2018 | Vol. 6 | Iss. 16 | e13824
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and -2 (p44 and p42 MAPK, respectively) when phospho-
rylated at T202 and Y204 (4370) and the rabbit polyclonal
antibody anti-ERK1/2 (9102) were from Cell Signalling
(Danvers, MA). The goat polyclonal anti-mouse TNF-a
(MAB4101) and antiadiponectin (AF1119) antibodies
were from R&D systems (Minneapolis, MN). The rabbit
polyclonal antibody antinitrotyrosine (AB5411) was from
Millipore Sigma (St. Louis, MO). The rabbit polyclonal
antibody anti-UCP-1 (PA1-24894 was from Thermo
Fisher (Rockford, IL). Protein loading in the gels was
evaluated with a mouse monoclonal anti-GADPDH
(ab9485) from Abcam (San Francisco, CA).
Statistical analyses
Values are reported as means  SEM unless specified
otherwise. Statistical significance was determined by t test
when two groups were compared (metabolic parameters),
by one-way ANOVA (GTT and ITT) or by two-way
ANOVA, followed by Tukey0s multiple comparison post
hoc test when multiple groups were compared. We
assigned significance at P < 0.05. In all the figures, *
P < 0.05, ** P < 0.01. All analyses were performed using
GraphPad Prism 6 (GraphPad Software, San Diego, CA).
Results
C21-treatment improves insulin sensitivity
and glucose tolerance in male C57Bl/6 mice
Treatment with C21 did not modify body weight of the
animals. Body weight of the mice was 28  2 g at treat-
ment start and 31  1 g at the end of treatment in both,
the vehicle and the C21-treated groups of animals
(Table 1). Remarkably, blood glucose levels were signifi-
cantly lower in mice treated chronically with C21
(20  2% reduction; P < 0.01 versus control values).
This finding is in accordance with the observation that
C21-treated mice displayed improved glucose handling as
shown in a GTT (Fig. 1A and B). The area under the
curve for the GTT was significantly lower in C21-treated
mice (Fig. 1B; P < 0.05 vs. the control group). These
changes were associated with augmented insulin sensitiv-
ity in C57Bl/6 mice (Fig. 1C and D). The area under the
curve for the ITT was significantly lower in C21-treated
mice compared to the saline-treated control group
(Fig. 1D; P = 0.0106 vs. nontreated control animals). The
beneficial change in glucose handling in the C21-treated
group coincided with unaltered circulating levels of insu-
lin and triglycerides and with a marginal but although
not significant decrease in the levels of cholesterol com-
pared to control.
C21-treatment induces changes in the
insulin signaling pathway downstream of
the insulin receptor in insulin-target tissues
of C57Bl/6 mice in vivo
To investigate the possible mechanism of the C21-
mediated improvement of glucose tolerance and insulin
sensitivity, we analyzed the in vivo status of main insulin
signaling components in insulin-target tissue of treated
mice. As expected, insulin itself let to a significant
increase in the phosphorylation of the insulin receptor,
Akt and ERK1/2 in liver, adipose tissue and skeletal mus-
cle (Fig. 2A–I). Basal- or insulin-induced insulin receptor
phosphorylation levels were not altered by C21 treatment
in all three organs (Fig. 2A–C). In the liver, treatment
with C21 induced a significant increase in the basal, but
not in the insulin-induced phosphorylation of Akt at
Ser473 when compared with control mice (Fig. 2D;
P < 0.01), In contrast, in adipose tissue, basal phosphory-
lation of Akt at Ser473 was unchanged by C21 treatment,
but the insulin-induced phosphorylation levels of this
Table 1. Anthropometric and biochemical markers of the experimental animals.
Parameter Control C21
Body weight, g
Beginning of study 28  2 (12) 28  2 (12)
End of study 32  1 (10) 32  1 (11)
Glucose, mg/dL 169  23 (10) 138  19 (12)1
Insulin, ng/mL 0.4  0.09 (5) 0.43  0.07 (6)
Triglycerides, mg/dL 46  4(5) 42  5 (6)
Cholesterol, mg/dL 72  3(5) 59  4 (6)
Epididymal adipose tissue weight, g 0.42  0.03 (10) 0.34  0.04 (12)
Values are means  SD. The number of samples used for each determination (n) is shown in parentheses.
1P < 0.01 when compared with control mice.
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kinase at Ser473 were significantly increased by AT2R
stimulation when compared with insulin-treated control
mice (49  7% increase, P < 0.05; Fig. 2E). Notably, in
skeletal muscle of C57Bl/6 mice, phosphorylation of Akt
at Ser473 remained unaltered after C21 treatment both in
basal conditions and after insulin stimulation (Fig. 2F).
Treatment with C21 induced a tissue-specific modulation
of ERK1/2 phosphorylation. Basal phosphorylation levels
of ERK1/2 at Thr202 and Tyr204, indicative of activation
of these enzymes, were markedly increased in liver of
C21-treated mice when compared with control mice (ap-
proximately 4-fold increase; P < 0.01; Fig. 2G), but not
in adipose tissue and skeletal muscle (Fig. 2H and I). In
contrast, C21 administration inhibited the insulin-
mediated phosphorylation of ERK1/2 in all analyzed tis-
sues. (Fig. 2G–I).
Treatment with C21 decreases adipocyte
size in C57Bl6/mice
As shown in Table 1, C21 treatment induced an apparent
decrease in absolute epididymal adipose tissue weight, but
this change was not statistically significant (P = 0.138).
As shown in Figure 3A and C, the mean area of adipo-
cytes from epididymal fat was significantly lower in mice
treated with C21 (1858  79 lm2) when compared with













































































Figure 1. Chronic administration of compound 21 improves glucose tolerance and insulin sensitivity. (A) GTT. (B) calculated area under the
curve from the GTT in control and C21-treated mice. (C) insulin tolerance test (ITT). (D) calculated area under the curve from the ITT in control
and C21-treated mice. Mice were fasted for 6 h prior to basal glucose monitoring (as described in Materials and Methods) and subsequently
injected i.p. with a 20% glucose solution (w/v). Blood was reanalyzed at 15, 30, 45, 60, and 120 min postinjection (C21, n = 12 per group;
control, n = 10 per group. Data are represented as mean  SEM. and analyzed by one-way ANOVA followed by Tukey0s multiple comparison t
tests where *P < 0.05 vs. control mice. GTT, glucose tolerance test.
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control mice (2999  152 lm2). The proportion of cells
in the 25–50 lm and 51–75 lm diameter range was
higher in adipose tissue from C21-treated mice that in
control mice (P < 0.01; Fig. 3B). In contrast, C21-treated
mice showed a lower proportion of cells in the 76–
100 lm size; Fig. 3B). No significant changes were
observed between C21-treated mice and control mice in
the highest size range analyzed (>100 lm), but the num-
ber of these cells was generally very low.
The enhanced insulin sensitivity of
C21-treated mice is accompanied by
increased abundance of adiponectin and
UCP-1 in white adipose tissue
Given that the enhanced insulin sensitivity and glucose
tolerance observed after C21 treatment was associated
with decreased adipocyte size, we performed further eval-
uation of adipose tissue status. Treatment with C21
induced a significant increase in adiponectin abundance
in epididymal adipose tissue assessed by both western
blotting (WB) and IHC (approximately twofold; P < 0.01
vs. control values); (Fig. 4A and B). This finding was con-
sistent with a significant increase in UCP-1 abundance in
this tissue (approximately 3-fold; P < 0.01 vs. control val-
ues Fig. 4C and D). There was no significant difference in
the content of the proinflammatory cytokine TNF-a in
adipose tissue between the two experimental groups
(Fig. 5A and B), Nitrotyrosine levels in adipose tissue
proteins were measured as a parameter of oxidative/ni-
trosative stress. The levels of proteins nitrated at Tyr resi-
dues were similar between C21-treated and saline-injected
controls (Fig. 5C and D).
Discussion
Our findings show that C57BL/6 mice exposed to chronic,
systemic pharmacological AT2R agonism with C21 display
decreased glycemia, enhanced glucose tolerance, and
improved insulin sensitivity, suggesting an active role of
the AT2R in the modulation of glycemic control under











Figure 2. Chronic administration of compound 21 modulates liver, adipose tissue, and skeletal muscle insulin signaling. Western blot analysis
of tissue from control saline-treated and C21-treated mice after acute injection with insulin (+) or vehicle (). (A–C) Phosphorylation levels of
the IR b-subunit at tyrosine (Y) residues in were determined in immunoprecipitated samples using antiphosphotyrosine antibodies as described
in Materials and Methods. D–F: Specific antibodies were used to detect phosphorylation of Akt at Serine (S) 473. (G–I) Phosphorylation of
ERK1/2 at activating residues Threonine (T) 202 and Tyrosine (Y) 204; (C21, n = 4–5 per group; control, n = 4–5 per group). Bar graphs
represent the quantification of phosphorylated (p) IR at tyrosine (Y) residues, Akt at Ser473 (S473) and ERK1/2 at Threonine 202 and Tyrosine
204 (T202/Y204) related to the abundance of the corresponding protein as measured with anti-IRb, anti-Akt, and anti-ERK1/2 antibodies. (J)
GADPH abundance was measured as a loading control in the same samples. Data are represented as mean  SEM and analyzed by two-way
ANOVA followed by Tukey0s test where *P < 0.05 and **P < 0.01 when compared with the group connected by a line. IR, insulin receptor.
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
2018 | Vol. 6 | Iss. 16 | e13824
Page 7
D. Tomas Quiroga et al. C21 Improves Insulin Sensitivity in C57Bl/6 Mice
improvement of glucose homeostasis is associated with an
activation of Akt and ERK1/2 under basal conditions in
the liver and with an enhancement of insulin-induced Akt
activation in adipose tissue. Concomitantly, C21 treat-
ment led to a blunted insulin response as indicated by an
inhibition of insulin-induced ERK1/2 activation in both
skeletal muscle and adipose tissue. Adipose tissue appears
as a major target of AT2R agonism and, presumably,
mediates many of the positive metabolic changes induced
by C21. Specifically, C21 treatment was associated with
decreased adipocyte size, increased levels of the insulin-
sensitizing adipokine adiponectin and augmented UCP-1
levels, a marker of adipose tissue browning.
Previous reports have shown an improvement of insu-
lin action and amelioration of insulin resistance after C21
treatment in different rodent models of insulin resistance
and type 2 diabetes, including KK-Ay diabetic mice
(Ohshima et al. 2012), high-fat/high-fructose fed rats
(Shum et al. 2013), STZ-diabetic adult and neonatal rats















































Figure 3. Chronic administration of compound 21 decreases adipocyte size. Epididymal adipose tissue was prepared for histology. Paraffin
sections (3 lm) were stained with hematoxylin and eosin and images acquired as described in Materials and Methods section. (A)
Representative histology images were obtained in adipose tissue sections at x10 magnification. (B) Adipocyte size distribution in control and
C21-treated mice. The cell size of 200 adipocytes was measured in four different microscopic fields for each sample, and the average was used
as the value of each sample (C21, n = 4 per group; control, n = 4 per group). Data are represented as mean  SEM. and analyzed by two-way
ANOVA followed by Tukey0s multiple comparison t tests where ** P < 0.01 when compared with the respective control diameter range. (C)
Adipocyte area was calculated from adipocyte diameters measured in panel B (C21, n = 4 per group; control, n = 4 per group). Data are
presented as means  SEM and analyzed by unpaired two-tailed Student’s t test where ** P < 0.01 when compared with control mice.
2018 | Vol. 6 | Iss. 16 | e13824
Page 8
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
C21 Improves Insulin Sensitivity in C57Bl/6 Mice D. Tomas Quiroga et al.
fatty rats (Castoldi et al. 2014). Our results are consistent
with these results and particularly, with those obtained in
normal male Sprague–Dawley rats where C21 administra-
tion increased glucose tolerance and insulin sensitivity
through an apparent insulinotropic effect (Shao et al.
2014). In line with these findings, our current results
indicate that AT2R modulates insulin action under physi-
ological conditions and reinforce the notion that AT2
agonism might have therapeutic potential in the manage-
ment of diabetes and its associated complications.
It has been previously shown that chronic treatment
with AT2R agonists reduces the size of hypertrophic adi-
pocytes and adipose tissue mass in rodents fed with high-
fat diet (Shum et al. 2013), suggesting the favorable
effects of AT2R activation for obesity. We showed that
treatment with C21 was associated with decreased adipo-
cyte area, resulting from decreased number of large adi-
pocytes and increased number of new, small adipocytes.
In humans, adipose cell enlargement, in association with
decreased expression of lipogenic genes, and expansion of
visceral adipose tissue and intrahepatic fat are mediators
of obesity-related insulin resistance (Salans et al. 1968;
McLaughlin et al. 2016). Thus, the reduction in adipocyte
size in C21-treated mice could be considered as an addi-
tional parameter of enhanced insulin action originating
from AT2R activation.
Angiotensin II through the AT1R, has been shown to
attenuate Akt activity through an ERK1/2-dependent
mechanism (D€unner et al. 2013). Interestingly, our cur-
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Figure 4. Chronic administration of compound 21 increases the abundance of adiponectin and UCP-1 in adipose tissue. (A) and (C)
Abundance of adiponectin and UCP-1 in adipose tissue as determined by western blotting. (B) and (D) Levels of adiponectin and UCP-1 as
determined by immunohistochemistry. Quantification of specific bands was performed with Gel-Pro Analyzer software. (A) and (C) Scatter dot
plots show individual values and superimposed bar graphs represent the means  S.E. (B) and (D) Positive adiponectin and UCP-1 staining was
quantified using Image-Pro Plus 4.5 software. Data were analyzed by unpaired two-tailed Student’s t test, where **P < 0.01 when compared
with saline-treated control mice. For adiponectin, (C21, n = 9 per group; control, n = 9 per group). For UCP-1, (C21, n = 9 per group, control,
n = 10 per group).
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activation of Akt and simultaneously inhibits insulin-sti-
mulated ERK1/2 activation in adipose tissue. These data
are in accordance with a recent study performed in iso-
lated mouse adipocytes showing that C21 increases Akt
and AMPK activation through a mechanism that might
involve attenuation of ERK1/2 phosphorylation (Than
et al. 2017). The enhancement of insulin-stimulated Akt
activation in adipose tissue might contribute to the ability
of C21 to enhance glucose uptake in this tissue (Ohshima
et al. 2012). Noteworthy, chronic blockade of the AT2R
by administration of PD123319 resulted in decreased
insulin signaling in liver and adipose tissue but did not
modify the status of the insulin signaling system in skele-
tal muscle (Mu~noz et al. 2017). Our current results and
previous findings suggest that glucose handling of the
skeletal muscle is unaltered after modulation (antagonism
or agonist) of the AT2R in healthy animals in vivo. This
could be ascribed to the low levels of AT2R compared to
AT1R present in this tissue. This situation might change
during pathological conditions where AT2R largely such
as skeletal muscle injury (Painemal et al. 2013) and also
in diabetic states (Lee et al. 2008a). In this aspect, our
studies do not agree with a recent report performed in
rats, showing that a short-term C21 infusion enhances
insulin delivery and action in muscle (Yan et al. 2018).
This could be ascribed to the several factors, including
differences in the duration of the experimental protocol
as well as the dose employed.
A B
C D
Figure 5. Parameters of inflammation/nitrosative stress are unaltered in adipose tissue after chronic administration of compound 21. (A) and
(B) Levels of TNF-a determined by WB and IHC. (C) and (D) levels of nitrotyrosine determined by WB and IHC. Quantification of specific bands
was performed with Gel-Pro Analyzer software. (C) For nitrotyrosine quantification, the intensity of the most predominant bands in the WB (of
unknown identity), with MWs of 53 and 65 kDa, respectively, were quantified in each sample. Bar graphs are the means  SE. (B) and (D)
Positive TNF-a and nitrotyrosine staining as detected by immunohistochemistry was quantified using Image-Pro Plus software. Data were
analyzed by unpaired two-tailed Student’s t test. C21, n = 9 per group, control, n = 12 per group for TNF-a quantification. For nitrotyrosine
quantification by Western blotting: C21, n = 6 per group; control, n = 6 per group and by immunohistochemistry: C21, n = 9 per group;
control, n = 9 per group. WB, western blotting.
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Regarding the mechanism by which AT2R agonist inhi-
bits insulin-induced phosphorylation of ERK1/2, it is well
established that the regulatory dephosphorylation of
ERK1/2 is mediated by protein-tyrosine-specific phos-
phatases, protein-serine/threonine phosphatases, and dual
specificity phosphatases (Roskoski 2012). Phosphatase
activation has been one of the first signals associated with
AT2R activation (Guimond and Gallo-Payet 2012; Carey
2017). MKP-1, is a key regulator of ERK1/2 activity.
AT2R-activated MKP-1 has been observed in various cell
types (Guimond and Gallo-Payet 2012). Activation of
MKP-1 by AT2R leads to a decrease in ERK1/2 activity
(Guimond and Gallo-Payet 2012), indicating that this
could be a potential mechanism by which C21 treatment
could lead to attenuation of insulin-induced ERK1/2 acti-
vation.
The increase in basal activation of ERK1/2 in the liver
is unexpected and might be the result of a direct action
of C21 in the hepatocytes. In previous studies performed
in neurite cells in vitro and in mouse heart in vivo, C21
incubation or administration has been shown to stimu-
late ERK1/2 phosphorylation (Wan et al. 2004; Kaschina
et al. 2008). Thus, it is possible that prolonged stimula-
tion of the AT2R might result in increased basal activa-
tion of ERK1/2. It remains to be determined whether
this change is linked to the enhanced insulin sensitivity
observed in C21-treated animals or it is unrelated to this
modification.
AT2Rs are expressed at low levels in healthy tissues
during physiologically quiescent states (Jones et al. 2008;
Padia and Carey 2013; Carey 2017). However, in the cur-
rent study, C21 exerted a positive modulation of insulin
action on normal mice indicating that these physiological
levels of AT2R are functional and capable of inducing a
metabolic response. Given that the affinity of C21 for the
AT2R is 25 000-fold higher than for the AT1R, there is a
strong indication that the insulin-sensitizing effects of
C21 are specifically mediated through the AT2R (Wan
et al. 2004).
Adiponectin is a major regulator of glucose and lipid
homeostasis via its insulin-sensitizing properties, and the
reduction in this adipokine is associated with the develop-
ment of metabolic syndrome and type 2 diabetes (Fang
and Sweeney 2006). Administration of adiponectin has
been shown to lower plasma glucose levels by improving
insulin action in mice (Berg et al. 2001; Kubota et al.
2002). Thus, the increase in adiponectin levels in adipose
tissue after treatment with C21 could be an important
contributor to the enhancement of insulin action
observed. Treatment with C21 has been reported to
increased serum adiponectin levels both in diet-induced
insulin-resistant rats (Shum et al. 2013) and in normal
mice (Than et al. 2017).
UCP-1 is a brown adipocyte-specific protein with a key
role in the thermogenic process. It promotes mitochon-
drial respiration and heat generation by decreasing the
proton gradient generated in oxidative phosphorylation,
hence the mitochondrial membrane potential (Krauss
et al. 2005). It has been shown that both AT1R antagonism
(Tsukuda et al. 2016) and incubation with C21 (Than
et al. 2017) increase UCP-1 levels in mouse adipocytes and
that in the presence of an AT1R blocker, angiotensin II
through AT2R mimics this upregulating effect (Than et al.
2017). We found that UCP-1 levels are significantly
increased in mouse adipose tissue after chronic administra-
tion of C21 reinforcing the notion that AT2R agonism can
induce adipocyte browning. Given the importance of the
browning of adipose tissue in regulating energy metabo-
lism and its therapeutic implication for the treatment of
obesity, AT2R modulation appears as a very attractive
therapeutic approach to treat obesity, insulin resistance,
and metabolic syndrome-like states.
Perspectives and significance
Prolonged treatment with the AT2R agonist C21 reduces
blood glucose levels and enhances insulin sensitivity and
glucose tolerance in C57Bl/6 mice. These beneficial effects
were not related to an increase in insulin production since
circulating insulin levels remained unaltered after treat-
ment with C21. Interestingly, a potential molecular mecha-
nism behind the beneficial effects of C21 could be the
modulation of the in vivo insulin signaling of adipose tis-
sue as shown by an improved response to insulin in terms
of Akt phosphorylation associated with a drastic attenua-
tion of insulin-stimulated ERK1/2 activation. We also
observed that changes in insulin signaling were tissue-spe-
cific: while insulin signaling was mainly unaltered in skele-
tal muscle, the liver of C21-treated mice showed increased
basal activation of both Akt and ERK1/2. Altered insulin
signaling in the liver indicates a potential participation of
this tissue in enhanced insulin action, presumably, involv-
ing inhibition of gluconeogenesis. However, this hypothe-
sis requires further exploration. Modulation of adipose
tissue function should also be considered an important
contributor to the observed metabolic changes. Both adi-
ponectin and uncoupling protein-1 levels were upregulated
in adipose tissue after the chronic agonism of the AT2R.
Thus, chronic AT2R agonism improves glucose homeosta-
sis and supports the therapeutic potential of AT2R modu-
lation in metabolic diseases.
Acknowledgments
This research has been supported by access to proprietary
material provided by Vicore Pharma AB.
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
2018 | Vol. 6 | Iss. 16 | e13824
Page 11
D. Tomas Quiroga et al. C21 Improves Insulin Sensitivity in C57Bl/6 Mice
Conflict of Interest
UMS received modest research support (free drug supply;
financial support for attending conferences) from Vicore
Pharma, which is the company owning C21. UMS is cur-
rently employed part-time by Vicore Pharma, but has not
been employed during the conduct of the study and the
analysis of data.
References
Allen, A. M., J. Zhuo, and F. A. Mendelsohn. 1999.
Localization of angiotensin AT1 and AT2 receptors. J. Am.
Soc. Nephrol. 11:S23–S29.
Berg, A. H., T. P. Combs, X. Du, M. Brownlee, and P. E.
Scherer. 2001. The adipocyte-secreted protein Acrp30
enhances hepatic insulin action. Nat. Med. 7:947–953.
Booz, G. W., and K. M. Baker. 1996. Role of type 1 and type 2
angiotensin receptors in angiotensin II-induced
cardiomyocyte hypertrophy. Hypertension 28:635–640.
Boucher, J., A. Kleinridders, and C. R. Kahn. 2014. Insulin
receptor signaling in normal and insulin-resistant states.
Cold Spring Harb. Perspect. Biol. 6: a00 9191.
Carey, R. M. 2017. Update on angiotensin AT2 receptors.
Curr. Opin. Nephrol. Hypertens. 26:91–96.
Castoldi, G., C. R. di Gioia, C. Bombardi, S. Maestroni, R.
Carletti, U. M. Steckelings, et al. 2014. Prevention of
diabetic nephropathy by compound 21, selective agonist of
angiotensin type 2 receptors, in Zucker diabetic fatty rats.
Am. J. Physiol. Renal Physiol. 307:F1123–F1131.
Chai, W., W. Wang, J. Liu, E. J. Barrett, R. M. Carey, W. Cao,
et al. 2010. Angiotensin II type 1 and type 2 receptors
regulate basal skeletal muscle microvascular volume and
glucose use. Hypertension 55:523–530.
Chai, W., W. Wang, Z. Dong, W. Cao, and Z. Liu. 2011.
Angiotensin II receptors modulate muscle microvascular and
metabolic responses to insulin in vivo. Diabetes 60:2939–
2946.
Chow, B. S. M., C. Koulis, P. Krishnaswamy, U. M.
Steckelings, T. Unger, M. E. Cooper, et al. 2016. The
angiotensin II type 2 receptor agonist Compound 21 is
protective in experimental diabetes-associated
atherosclerosis. Diabetologia 59:1778–1790.
D€unner, N., C. Quezada, F. A. Berndt, J. Canovas, and C. V.
Rojas. 2013. Angiotensin II signaling in human preadipose
cells: participation of ERK1,2-dependent modulation of Akt.
PLoS ONE 8:e75440.
Fang, X., and G. Sweeney. 2006. Mechanisms regulating energy
metabolism by adiponectin in obesity and diabetes.
Biochem. Soc. Trans. 34:798–801.
Favre, G. A., V. L. Esnault, and E. Van Obberghen. 2015.
Modulation of glucose metabolism by the renin-angiotensin-
aldosterone system. Am. J. Physiol. Endocrinol. Metab. 308:
E435–E449.
Ferrario, C. M., S. Ahmad, S. Nagata, S. W. Simington, and J.
Varagic, J. Kon, et al. 2014. An evolving story of
angiotensin-II-forming pathways in rodents and humans.
Clin. Sci. 126:461–469.
Folli, F., C. R. Kahn, H. Hansen, J. L. Bouchie, and E. P.
Feene. 1997. Angiotensin II inhibits insulin signaling in
aortic smooth muscle cells at multiple levels. A potential
role for serine phosphorylation in insulin/angiotensin II
crosstalk. J. Clin. Invest. 100:2158–2169.
Guimond, M.-O., and N. Gallo-Payet. 2012. How does
angiotensin AT2 receptor activation help neuronal
differentiation and improve neuronal pathological
situations? Front. Endocrinol. 3:164.
Henriksen, E. J. 2007. Improvement of insulin sensitivity by
antagonism of the renin-angiotensin system. Am. J. Physiol.
Regul. Integr. Comp. Physiol. 293:R974–R980.
Jones, E. S., A. Vinh, C. A. McCarthy, T. A. Gaspari, and R. E.
Widdop. 2008. AT2 receptors: functional relevance in
cardiovascular disease. Pharmacol. Ther. 120:292–316.
Karnik, S. S., H. Unal, J. R. Kemp, K. C. Tirupula, S. Eguchi,
P. M. Vanderheyden, et al. 2015. International union of
basic and clinical pharmacology. XCIX. Angiotensin
receptors: interpreters of pathophysiological angiotensinergic
stimulis. Pharmacol. Rev. 67: 754–819.
Kaschina, E., A. Grzesiak, J. Li, A. Foryst-Ludwig, M. Timm,
F. Rompe, et al. 2008. Angiotensin II type 2 receptor
stimulation: a novel option of therapeutic interference with
the renin-angiotensin system in myocardial infarction?
Circulation 118:2523–2532.
Krauss, S., C. Y. Zhang, and B. B. Lowell. 2005. The
mitochondrial uncoupling-protein homologues. Nat. Rev.
Mol. Cell Biol. 6:248–261.
Kubota, N., Y. Terauchi, T. Yamauchi, T. Kubota, M. Moroi,
J. Matsui, et al. 2002. Disruption of adiponectin causes
insulin resistance and neointimal formation. J. Biol. Chem.
277:25863–25866.
Lee, J. H., S. Xia, and L. Ragolia. 2008a. Upregulation of AT2
receptor and iNOS impairs angiotensin II-induced
contraction without endothelium influence in young
normotensive diabetic rats. Am. J. Physiol. Regul. Integr.
Comp. Physiol. 295:R144–R154.
Lee, M. H., H. K. Song, G. J. Ko, Y. S. Kang, S. Y. Han, K. H.
Han, et al. 2008b. Angiotensin receptor blockers improve
insulin resistance in type 2 diabetic rats by modulating
adipose tissue. Kidney Int. 74:890–900.
Lemarie, C. A., and E. L. Schiffrin. 2010. The angiotensin II
type 2 receptor in cardio-vascular disease. J. Renin.
Angiotensin. Aldosterone Syst. 11:19–31.
Leung, K. K., J. Liang, S. Zhao, W. Y. Chan, and P. S. Leung.
2014. Angiotensin II type 2 receptor regulates the
development of pancreatic endocrine cells in mouse
embryos. Dev. Dyn. 243:415–427.
McLaughlin, T., C. Craig, L. F. Liu, D. Perelman, C. Allister,
D. Spielman, et al. 2016. Adipose cell size and regional fat
2018 | Vol. 6 | Iss. 16 | e13824
Page 12
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
C21 Improves Insulin Sensitivity in C57Bl/6 Mice D. Tomas Quiroga et al.
deposition as predictors of metabolic response to
overfeeding in insulin-resistant and insulin-sensitive humans
diabetes. Diabetes 65:1245–1254.
Miyata, N., F. Park, X. F. Li, and A. W. Jr Cowley. 1999.
Distribution of angiotensin AT1 and AT2 receptor subtypes
in the rat kidney. Am. J. Physiol. Renal Physiol. 277:F437–
F446.
Mu~noz, M. C., J. F. Giani, F. P. Dominici, D. Turyn, and J. E.
Toblli. 2009. Long-term treatment with an angiotensin II
receptor blocker decreases adipocyte size and improves
insulin signaling in obese Zucker rats. J. Hypertens.
27:2020–2409.
Mu~noz, M. C., V. Burghi, J. G. Miquet, I. A. Cervino, D. T.
Quiroga, L. Mazziotta, et al. 2017. Chronic blockade of the
AT2 receptor with PD123319 impairs insulin signaling in
C57BL/6 mice. Peptides 88:37–45.
Nag, S., M. A. Khan, P. Samuel, Q. Ali, and T. Hussain. 2015.
Chronic angiotensin AT2R activation prevents high-fat diet-
induced adiposity and obesity in female mice independent
of estrogen. Metabolism 64:814–825.
Namsolleck, P., C. Recarti, S. Foulquier, U. M. Steckelings,
and T. Unger. 2014. AT2 receptor and tissue injury:
therapeutic implications. Curr. Hypertens. Rep. 16:416.
Noll, C., S. M. Labbe, S. Pinard, M. Shum, L. Bilodeau, L.
Chouinard, et al. 2015. Postprandial fatty acid uptake and
adipocyte remodeling in angiotensin type 2 receptor-
deficient mice fed a high-fat/high-fructose diet. Adipocyte
5:43–52.
Ohshima, K., M. Mogi, F. Jing, J. Iwanami, K. Tsukuda, L. J.
Min, et al. 2012. Direct angiotensin II type 2 receptor
stimulation ameliorates insulin resistance in type 2 diabetes
mice with PPARc activation. PLoS ONE 7:e48387.
Ozono, R., Z. Q. Wang, A. F. Moore, T. Inagami, H. M.
Siragy, and R. M. Carey. 1997. Expression of the subtype 2
angiotensin (AT2) receptor protein in rat kidney.
Hypertension 30:1238–1246.
Padia, S. H., and R. M. Carey. 2013. AT2 receptors: beneficial
counter-regulatory role in cardiovascular and renal function.
Pflugers Arch. 465:499–510.
Painemal, P., M. J. Acu~na, C. Riquelme, E. Brandan, and C.
Cabello-Verrugio. 2013. Transforming growth factor type
beta 1 increases the expression of angiotensin II receptor
type 2 by a SMAD- and p38 MAPK-dependent mechanism
in skeletal muscle. BioFactors 39:467–475.
Paulis, L., S. Foulquier, P. Namsolleck, C. Recarti, U. M.
Steckelings, and T. Unger. 2016. Combined angiotensin
receptor modulation in the management of cardio-metabolic
disorders. Drugs 76:1–12.
Roskoski, R. Jr. 2012. ERK1/2 MAP kinases: structure,
function, and regulation. Pharmacol. Res. 66:105–143.
Salans, L. B., J. L. Knittle, and J. Hirsch. 1968. The role of
adipose cell size and adipose tissue insulin sensitivity in the
carbohydrate intolerance of human obesity.J. Clin. Invest.
47:153–165.
Samuel, P., M. A. Khan, S. Nag, T. Inagami, and T. Hussain.
2013. Angiotensin AT(2) receptor contributes towards
gender bias in weight gain. PLoS ONE 8:e48425.
Shao, C., I. H. Zucker, and L. Gao. 2013. Angiotensin type 2
receptor in pancreatic islets of adult rats: a novel
insulinotropic mediator. Am. J. Physiol. Endocrinol. Metab.
305:E1281–E1291.
Shao, C., L. Yu, and L. Gao. 2014. Activation of angiotensin type 2
receptors partially ameliorates streptozotocin-induced diabetes in
male rats by islet protection. Endocrinology 155:793–804.
Shiuchi, T., M. Iwai, H. S. Li, L. Wu, L. J. Min, J. M. Li, et al.
2004. Angiotensin II type-1 receptor blocker valsartan
enhances insulin sensitivity in skeletal muscles of diabetic
mice. Hypertension 43:1003–1010.
Shum, M., S. Pinard, M. O. Guimond, S. M. Labbe, C.
Roberge, J. P. Baillargeon, et al. 2013. Angiotensin II type 2
receptor promotes adipocyte differentiation and restores
adipocyte size in high-fat/high-fructose diet-induced insulin
resistance in rats. Am. J. Physiol. Endocrinol. Metab. 304:
E197–E210.
Than, A., S. Xu, R. Li, M. S. Leow, L. Sun, and P. Chen. 2017.
Angiotensin type 2 receptor activation promotes browning
of white adipose tissue and brown adipogenesis. Signal
Transduct. Target Ther. 2:17022.
Tsukuda, K., M. Mogi, J. Iwanami, H. Kanno, H. Nakaoka, X. L.
Wang, et al. 2016. Enhancement of adipocyte browning by
angiotensin II type 1 receptor blockade. PLoS ONE 11:e0167704.
Wan, Y., C. Wallinder, B. Plouffe, H. Beaudry, A. K.
Mahalingam, X. Wu, et al. 2004. Design, synthesis, and
biological evaluation of the first selective nonpeptide AT2
receptor agonist. J. Med. Chem. 47:5995–6008.
Wang, Z. Q., A. F. Moore, R. Ozono, H. M. Siragy, and R. M.
Carey. 1998. Immunolocalization of subtype 2 angiotensin II
(AT2) receptor protein in rat heart. Hypertension 32:78–83.
Wang, L., Y. Wang, X. Y. Li, and P. S. Leung. 2017.
Angiotensin II type 2 receptor activation with compound 21
augments islet function and regeneration in streptozotocin-
induced neonatal rats and human pancreatic progenitor
cells. Pancreas 46:395–404.
Yan, F., Z. Yuan, N. Wang, R. M. Carey, K. W. Aylor, L.
Chen, et al. 2018. Direct activation of angiotensin II type 2
receptors enhances muscle microvascular perfusion,
oxygenation, and insulin delivery in male rats.
Endocrinology 159:685–695.
Yvan-Charvet, L., P. Even, M. Bloch-Faure, M. Guerre-Millo,
N. Moustaid-Moussa, P. Ferre, et al. 2005. Deletion of the
angiotensin type 2 receptor (AT2R) reduces adipose cell size
and protects from diet-induced obesity and insulin
resistance. Diabetes 54:991–999.
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
2018 | Vol. 6 | Iss. 16 | e13824
Page 13
D. Tomas Quiroga et al. C21 Improves Insulin Sensitivity in C57Bl/6 Mice
